- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
eResearchTechnology files initial public offering
eResearchTechnology (eRT) has filed for an initial public offering as part of an overall effort to reposition its parent company, Premier Research Worldwide (PRWW), as a provider of Internet clinical
eResearchTechnology (eRT) has filed for an initial public offering as part of an overall effort to reposition its parent company, Premier Research Worldwide (PRWW), as a provider of Internet clinical trials software. Philadelphia-based eRT provides diagnostic services and research capabilities over the Internet to accelerate clinical research trials. Its products are combined into electronic research networks, which connect sponsors, clinical research organizations, physicians, and patients via proprietary database technology and software.
In addition to filing the eRT IPO last month, PRWW recently sold off its clinical research organization, launched eRT, acquired 10% of a Web-hosting company called Medical Advisory Systems, and announced a five-year contract between eRT and MAS whereby MAS will provide application hosting for eRTs products. PRWW will funnel its business offerings through the eRT subsidiary, and essentially act as a holding company. MAS, which is also the ASP for americasdoctor.com on AOL, will use part of the PRWW investment to upgrade its equipment to host eRTs applications and will allow eRT to access MASs 24/7 physician call center as support for several eRT programs, including eSafetyNet and eECG.
© 2000 Miller Freeman, Inc., a United News & Media company.
- Search again
- Homepage
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
